Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 16, 2021 08:00 ET | Source: Zogenix, Inc

Zogenix Presents New Data from a Study Highlighting the Impact of Treatment with FINTEPLA® (Fenfluramine) Oral Solution on Dravet Syndrome Patients, Caregivers, and Families at Virtual AAN 2021

Seizure Related Benefits noted by caregivers included reduction in frequency, fewer triggers causing seizures, and shorter recovery time when seizure did occur.Non-Seizure benefits most commonly noted...
April 08, 2021 08:00 ET | Source: Zogenix, Inc

Zogenix to Participate in the 20th Annual Needham Virtual Healthcare Conference

EMERYVILLE, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen...
March 25, 2021 08:00 ET | Source: Zogenix, Inc

Zogenix to Participate in the Stifel 3rd Annual CNS Day

EMERYVILLE, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen...
March 02, 2021 08:00 ET | Source: Zogenix, Inc

Zogenix to Participate in the Raymond James Institutional Investors Conference

EMERYVILLE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Michael...
February 25, 2021 16:01 ET | Source: Zogenix, Inc

Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

Positive momentum continues for U.S. launch of FINTEPLA® (fenfluramine) oral solution in Dravet syndrome, with total net product sales of $8.1 million in the fourth quarter; total net sales of $9.6...
February 18, 2021 08:00 ET | Source: Zogenix, Inc

Zogenix to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

EMERYVILLE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will...
February 11, 2021 08:00 ET | Source: Zogenix, Inc

Zogenix to Release Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25

EMERYVILLE, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial...
February 01, 2021 03:00 ET | Source: Zogenix, Inc

Zogenix’s FINTEPLA® (Fenfluramine) Oral Solution Now Available in Germany for the Treatment of Seizures in Dravet Syndrome

FINTEPLA offers a new treatment option for patients in Germany with Dravet syndrome, a rare, devastating, infant-onset epilepsy marked by frequent seizures, medical emergencies, and developmental...
January 11, 2021 08:00 ET | Source: Zogenix, Inc

Zogenix Announces Preliminary, Unaudited Fourth Quarter 2020 Net Product Sales

Total FINTEPLA® preliminary, unaudited net product sales of approximately $8.1 million for the fourth quarterAs of December 31, 2020, 492 healthcare prescribers had completed FINTEPLA Risk Evaluation...
December 21, 2020 08:00 ET | Source: Zogenix, Inc

The European Commission Approves Zogenix’s FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome

Dravet syndrome is a rare, debilitating and difficult-to-treat lifelong epilepsy that begins in infancyEC approval is based on Phase 3 study data demonstrating that FINTEPLA safely and significantly...